News & Videos - THERALASE TECHS INC. TLTFF

You are currently viewing all stock exchange news of the financial instrument THERALASE TECHS INC. TLTFF regarding all markets in all languages.

> News ACCESSWIRE published a news.

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase ® Technologies Inc. (" Theralase ® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF )( FRA:TTX ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a Non-Brokered Private Placement (" NBPP ") offering ("...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Granted Canadian Cancer Vaccine Patent • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine. The recently issued patent is titled, " Vaccine Containing Cancer...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Release's 4Q2023 Interim Financial Statements • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements (" Financial Statements "). Theralase® will...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDCs ") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that it is hosting Advisory Board meetings to present the latest Study II interim clinical...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, donated two Theralase® TLC-2400 Cool Laser Therapy (" CLT ") systems to the University of Windsor to aid in the research...

Thank you Chart

> News ACCESSWIRE published a news.

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses is pleased to announce that Dr. Michael Jewett has joined Theralase®, in the role of an independent consultant, to assist...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a non-brokered private placement offering (" Offering ") of units ("...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses is providing an update regarding its Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC ") clinical study (" Study II ")....

Thank you Chart

> News ACCESSWIRE published a news.

Theralase Release’s 3Q2023 Interim Financial Statements • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / November 29 th , 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's 3Q2023 unaudited condensed interim consolidated Financial Statements (" Financial Statements...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has has successfully closed a non-brokered private placement offering (" Offering ") of...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") used for the safe and effective destruction of various cancers, bacteria and viruses, has commenced a non-brokered private placement of units of the Company (" Units ") to raise up to $CAN 1.5 M ("...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Announces Brokered LIFE Financing • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and viruses. Theralase® is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study • • ACCESSWIRE • Stocks

Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review Optimized TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria and...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Provides Update on Bladder Cancer Clinical Study • • ACCESSWIRE • Stocks

Theralase®'s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®'s Anti-Cancer Therapy Achieved a Complete Response TORONTO, ON / ACCESSWIRE / October 16, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical-stage pharmaceutical company dedicated to the research and development of light or radiation activated Photo Dynamic Compounds (" PDCs ") for the safe and effective destruction of various cancers, bacteria...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Files US Patent for Enhanced Immunotherapy • • ACCESSWIRE • Stocks

Theralase®'s Latest Preclinical Data Supports Combining Immunotherapy Drugs with Theralase® PDCs for Increased Cancer Destruction TORONTO, ON / ACCESSWIRE / October 5, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of Photo Dynamic Compounds (" PDCs "), in addition to the light and radiation systems that activate them, is focused on the safe and effective...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM) • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / September 27, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activatedPhoto Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses when light or radiation...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Grants Stock Options • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT ) ( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers, announces the grant of stock options. The Company has granted an aggregate of...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase(R) Closes Private Placement Equity Financing • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), is a clinical stage pharmaceutical company focused on the research, development and commercialization of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a...

Thank you Chart

> News ACCESSWIRE published a news.

Theralase Release’s 2Q2023 Interim Financial Statements • • ACCESSWIRE • Stocks

TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDCs "), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the Company's 2Q2023 unaudited condensed interim consolidated Financial...

Thank you Chart